Skip to main content
home / Industry sessions

Industry sessions

Satellite Symposiums

We are pleased to invite you to our Satellite Symposiums at ICNC2026 in Berlin. These sessions will bring together leading experts to discuss the latest advances, emerging research, and clinical insights in the field. Join us for engaging presentations, interactive discussions, and valuable networking opportunities with colleagues from around the world. We look forward to welcoming you.

Sessions

Session SAT01
Satellite Symposium 1 - MedTrace Pharma
May 17, 2026
12:10 - 13:00
Estrel A+B

15O-Water and aQuant is Coming: Is it the Ultimate in PET Myocardial Perfusion Quantification?
MedTrace Pharma A/S anticipates introducing a new ¹⁵O-water system to the market in the near future. The system produces ¹⁵O-water for immediate administration at the point of imaging, overcoming many of the logistical barriers that have historically limited its use. Combined with dedicated imaging software for streamlined quantification and interpretation, the MedTrace solution brings this gold-standard perfusion tracer into routine clinical practice—expanding access, improving workflow efficiency, and supporting more accurate, data-driven decision-making in nuclear cardiology.
Session SAT02
Satellite Symposium 2 - Blue Earth Diagnostics LTD
May 18, 2026
08:00 - 08:50
Estrel A+B

Coronary flow capacity: Its origin and practical application

This satellite symposium will focus on Coronary Flow Capacity (CFC), an integrated approach combining coronary flow reserve and absolute myocardial blood flow to provide a more comprehensive assessment of coronary circulation. Developed to improve the identification of clinically significant ischemia, CFC offers enhanced insight into both epicardial and microvascular disease. Through expert perspectives and practical examples, this session highlights how CFC can support more accurate diagnosis, improved risk stratification, and informed clinical decision-making in nuclear cardiology.
Session SAT03
Satellite Symposium 3 - BridgeBio Pharma
May 18, 2026
12:10 - 13:00
Estrel A+B

Optimizing Early Diagnosis of Cardiac Amyloidosis

The programme focuses on improving early diagnosis of ATTR-CM by highlighting the use of noninvasive imaging, recognizing early clinical warning signs, and addressing current limitations in diagnostic approaches. It also explores emerging diagnostic developments and the remaining challenges that may impact timely detection and treatment decisions.